Conmed (CNMD) Tops Q1 EPS by 5c, provides guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/3/2026
- Nasdaq ends higher as AI heavyweights rebound ahead of midterm results
- Apple shares slip amid guidance for tightening margins, slowing services growth
- Rising shorts cool U.S. large-cap positioning, cutting liquidation risk: Citi
- Apple's 'unprecedented' memory warning adds fuel to wobbly Micron, SK hynix trade
- Palantir raises 2026 revenue outlook after quarterly revenue nearly doubles on AI
Tweet
Share
E-mailGet Alerts CNMD Hot Sheet
Join SI Premium – FREE
Conmed (NYSE: CNMD) reported Q1 EPS of $0.79, $0.05 better than the analyst estimate of $0.74. Revenue for the quarter came in at $312.3 million versus the consensus estimate of $306.73 million.
GUIDANCE:
Conmed sees FY2024 EPS of $4.25-$4.35, versus the consensus of $4.33. Conmed sees FY2024 revenue of $1.33-1.355 billion, versus the consensus of $1.35 billion.
For earnings history and earnings-related data on Conmed (CNMD) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Ultragenyx Pharma (RARE) Misses Q3 EPS by 6c; Offers Guidance
- Everus Construction Group, Inc. (ECG) Tops Q3 EPS by 101c ; Offers Guidance
- Spyre Therapeutics, Inc. (SYRE) Misses Q3 EPS by 16c
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
